Drugs / Solabegron
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02938507 | Oct → Dec 2016 | overactive bladder | Velicept Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00501267 | Jun → Aug 2007 | overactive bladder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00427596 | Jan → Aug 2007 | overactive bladder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00401479 | Oct 2006 → ? | irritable bowel syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03594058 | Jul 2018 → Apr 2019 | overactive bladder | Velicept Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03475706 | Feb 2018 → Jan 2019 | overactive bladder | Velicept Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00343486 | May 2006 → ? | overactive bladder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Solabegron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03594058 ↗ |
| Known as | GW427353 | “A Two-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Four MR Formulations and Food Effect of GW427353 (Solabegron) in Healthy Adult Subjects” NCT00427596 ↗2“Oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo” NCT00343486 ↗ “Solabegron (GW427353)” NCT00401479 ↗ |
| Route | Oral | “Oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo” NCT00343486 ↗ |